Opendata, web and dolomites

3DLT SIGNED

3D Living Tissues

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 3DLT project word cloud

Explore the words cloud of the 3DLT project. It provides you a very rough idea of what is the project "3DLT" about.

efficient       data    tests    immuneonco    times    molecules    2019    spends    predictive    undertaking    rate    uncomplete    excluding    expenditure    printing    commercialization    develops    edge    node    industrial    expenditures    5bln    ematik    care    compartmentalization    resolution    clinical    once    equal    ip    customers    acquire    cosmetic    contrary    immunotherapies    3dln    asap    economic    alive    markets    regenerative    structure    revenue    feasibility    pharmacological    business    2bln    yearn    strategy    cell    entire    prometheus    drug    3d    preclinical    market    opportunity    connecting    share    wounds    cells    connect    cutting    ones    animal    proprietary    forecast    bioprinting    pharma    unreliable    estimating    strictly    safety    cancer    asymp    time    mln    corresponding    lymph    composition    price    remaining    1st    respect    living    tissues    drugs    companies    medicine    building    satisfy    96    fails    printed    reduce    40mln    performed    deeply    vitro    framework    trials    oncological    company    requests    commercial    ink    jan    human   

Project "3DLT" data sheet

The following table provides information about the project.

Coordinator
PROMETHEUS S.R.L. 

Organization address
address: VIA TRENTO 30
city: PARMA
postcode: 43122
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.prometheus3d.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROMETHEUS S.R.L. IT (PARMA) coordinator 50˙000.00

Map

 Project objective

Prometheus S.r.l. develops and markets 3D human like tissues for regenerative medicine and pharmacological tests. A proprietary 3D Bioprinting Technology enables Prometheus to make use of human living cells as ink, to building up 3D tissues equal for structure and features to the human ones. The human living cells are printed by a strictly controlled process with high resolution, remaining alive during the entire printing process and for a long time beyond. The cutting edge new tissues satisfy the requests of pharma/cosmetic companies to reduce R&D expenditures and times for new products commercialization. Prometheus will go-to-market in Jan 2019 with its 1st product: Ematik, for wounds care. In this framework, Prometheus is undertaking a new business opportunity: a 3D Lymph Node (3DLN) for the testing of new immunotherapies against cancer. The 96% of oncological drugs efficient/safety in preclinical tests, fails human clinical trials, with a 2,5Bln$ expenditure/drug. This high failure rate is due to in vitro tests performed with current unreliable tissues: uncomplete, with different cell composition and compartmentalization respect to the corresponding human once. Contrary, Prometheus’ 3D Lymph Node is equal to the human one for composition, structure and functionality, providing more predictive data. Each company tests 80 new molecules/year and spends ≈4 Mln$ for in vitro tests, excluding animal testing (≈4 Mln$). Market of products for immuneonco testing is estimated in 2Bln€. According to key topics, all potential EU customers yearn to find on the market, asap, at any price, a 3D Lymph Node as the one of Prometheus, whose features allow to rapidly acquire a 4% EU market share in 5 years (40Mln€). During the feasibility study we will assess 3DLN project economic feasibility, we will connect with potential customers, estimating deeply market share, defining a revenue forecast, connecting with industrial and commercial partners, define also an IP strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3DLT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "3DLT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

DD-SCAN (2019)

DD-SCAN – AI-based language and multimedia bias checker for corporate communication content

Read More